No connection

Search Results

ABBV vs HSTM

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
HSTM
HealthStream, Inc.
BEARISH
Price
$19.88
Market Cap
$589.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
HSTM
32.59
Forward P/E
ABBV
15.42
HSTM
23.12
P/B Ratio
ABBV
-146.66
HSTM
1.66
P/S Ratio
ABBV
6.5
HSTM
1.94
EV/EBITDA
ABBV
15.27
HSTM
14.2

Profitability

Gross Margin
ABBV
71.46%
HSTM
64.74%
Operating Margin
ABBV
35.5%
HSTM
3.64%
Profit Margin
ABBV
4.0%
HSTM
6.03%
ROE
ABBV
137.96%
HSTM
5.14%
ROA
ABBV
9.59%
HSTM
2.51%

Growth

Revenue Growth
ABBV
9.1%
HSTM
7.4%
Earnings Growth
ABBV
-88.7%
HSTM
-46.5%

Financial Health

Debt/Equity
ABBV
--
HSTM
0.05
Current Ratio
ABBV
0.72
HSTM
0.96
Quick Ratio
ABBV
0.47
HSTM
0.77

Dividends

Dividend Yield
ABBV
3.05%
HSTM
0.64%
Payout Ratio
ABBV
490.15%
HSTM
20.33%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
HSTM BEARISH

HSTM presents a contradictory profile: while the Piotroski F-Score of 7/9 indicates strong fundamental health and a clean balance sheet, the valuation is severely disconnected from intrinsic reality. The stock trades at $19.88, significantly above both its Graham Number ($12.82) and its growth-based intrinsic value ($4.27). This valuation gap is exacerbated by a collapse in earnings growth (-46.5% YoY) and a completely bearish technical trend (0/100). Despite low debt, the combination of crashing profitability and insider selling suggests a value trap scenario.

Strengths
Strong Piotroski F-Score (7/9) indicating operational health
Extremely low Debt/Equity ratio (0.05)
High Gross Margins (64.74%)
Risks
Severe earnings contraction (-46.5% YoY)
Significant overvaluation relative to Graham Number and Intrinsic Value
Bearish technical momentum (0/100 trend score)

Compare Another Pair

ABBV vs HSTM: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and HealthStream, Inc. (HSTM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile